A Phase 2 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in the Treatment of Patients With Post-transplant Recurrence of C3G or IC-MPGN (ISN 2022) - Apellis Medical Hub

A Phase 2 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in the Treatment of Patients With Post-transplant Recurrence of C3G or IC-MPGN

Share Via Email

Back to Conference Resources

IC-MPGN & C3G Congress Presentations International Society of Nephrology Frontiers Meeting (ISN) 2022

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.